A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

This study is testing a new drug called HS-10382 for people with chronic myeloid leukemia (CML) — a blood cancer — whose disease is not responding to or cannot tolerate existing targeted therapies called TKIs. HS-10382 works differently from current TKIs and may help patients resistant to them. **You may be eligible if...** - You are 18–74 years old - You have chronic myeloid leukemia in the chronic or accelerated phase - Your CML has a gene change called BCR-ABL1 or the Philadelphia chromosome - Your disease is resistant to or you cannot tolerate current TKI medications - You are in reasonably good health (ECOG 0–2) **You may NOT be eligible if...** - Your CML is currently well controlled on TKI therapy - Your CML has progressed to blast phase - You have had prior treatment with a BCR-ABL1 allosteric inhibitor - You have serious heart rhythm problems or low heart pumping function - You have had a heart attack or heart failure in the last 6 months - You have a history of pancreatitis - You have severe, uncontrolled high blood pressure or diabetes - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.